Clinical Trial Progress and Application of Immune Checkpoint Inhibitors in the Treatment of Small Cell Lung Cancer
Small cell lung cancer (SCLC) is a neuroendocrine tumor with fast progression, high malignancy, easy recurrence, and extremely poor prognosis. In the past 30 years, the clinical treatment strategy of SCLC has been mainly chemotherapy and radiotherapy, but the curative effect is not significant; the...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | article |
| Lenguaje: | ZH |
| Publicado: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/d5d30f7655854dbd91b98eec9541ca3e |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:d5d30f7655854dbd91b98eec9541ca3e |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:d5d30f7655854dbd91b98eec9541ca3e2021-11-19T06:49:15ZClinical Trial Progress and Application of Immune Checkpoint Inhibitors
in the Treatment of Small Cell Lung Cancer1009-34191999-618710.3779/j.issn.1009-3419.2021.102.41https://doaj.org/article/d5d30f7655854dbd91b98eec9541ca3e2021-11-01T00:00:00Zhttp://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.41https://doaj.org/toc/1009-3419https://doaj.org/toc/1999-6187Small cell lung cancer (SCLC) is a neuroendocrine tumor with fast progression, high malignancy, easy recurrence, and extremely poor prognosis. In the past 30 years, the clinical treatment strategy of SCLC has been mainly chemotherapy and radiotherapy, but the curative effect is not significant; the current immunotherapy of SCLC has gradually entered the clinic and has made certain progress. Tumor immunotherapy includes immune checkpoint inhibitors, tumor vaccines, cytokines, chimeric antigen receptor T-cell immunotherapy (CAR-T) therapy, etc. Currently, immune checkpoint inhibitors are the most widely used. This article summarizes the principles of immune checkpoint inhibitors and related drugs, summarizes their domestic and foreign clinical trials progress in SCLC treatment, reviews the biomarkers used in the therapy, and discusses its future development direction.Huiqiu ZHANGXiyang LIXichuan LIYanjun SUChinese Anti-Cancer Association; Chinese Antituberculosis Associationarticlelung neoplasmsimmunotherapyimmune checkpoint inhibitorsclinical trial progressbiomarkersNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ZHChinese Journal of Lung Cancer, Vol 24, Iss 11, Pp 790-795 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
ZH |
| topic |
lung neoplasms immunotherapy immune checkpoint inhibitors clinical trial progress biomarkers Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
| spellingShingle |
lung neoplasms immunotherapy immune checkpoint inhibitors clinical trial progress biomarkers Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Huiqiu ZHANG Xiyang LI Xichuan LI Yanjun SU Clinical Trial Progress and Application of Immune Checkpoint Inhibitors in the Treatment of Small Cell Lung Cancer |
| description |
Small cell lung cancer (SCLC) is a neuroendocrine tumor with fast progression, high malignancy, easy recurrence, and extremely poor prognosis. In the past 30 years, the clinical treatment strategy of SCLC has been mainly chemotherapy and radiotherapy, but the curative effect is not significant; the current immunotherapy of SCLC has gradually entered the clinic and has made certain progress. Tumor immunotherapy includes immune checkpoint inhibitors, tumor vaccines, cytokines, chimeric antigen receptor T-cell immunotherapy (CAR-T) therapy, etc. Currently, immune checkpoint inhibitors are the most widely used. This article summarizes the principles of immune checkpoint inhibitors and related drugs, summarizes their domestic and foreign clinical trials progress in SCLC treatment, reviews the biomarkers used in the therapy, and discusses its future development direction. |
| format |
article |
| author |
Huiqiu ZHANG Xiyang LI Xichuan LI Yanjun SU |
| author_facet |
Huiqiu ZHANG Xiyang LI Xichuan LI Yanjun SU |
| author_sort |
Huiqiu ZHANG |
| title |
Clinical Trial Progress and Application of Immune Checkpoint Inhibitors
in the Treatment of Small Cell Lung Cancer |
| title_short |
Clinical Trial Progress and Application of Immune Checkpoint Inhibitors
in the Treatment of Small Cell Lung Cancer |
| title_full |
Clinical Trial Progress and Application of Immune Checkpoint Inhibitors
in the Treatment of Small Cell Lung Cancer |
| title_fullStr |
Clinical Trial Progress and Application of Immune Checkpoint Inhibitors
in the Treatment of Small Cell Lung Cancer |
| title_full_unstemmed |
Clinical Trial Progress and Application of Immune Checkpoint Inhibitors
in the Treatment of Small Cell Lung Cancer |
| title_sort |
clinical trial progress and application of immune checkpoint inhibitors
in the treatment of small cell lung cancer |
| publisher |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association |
| publishDate |
2021 |
| url |
https://doaj.org/article/d5d30f7655854dbd91b98eec9541ca3e |
| work_keys_str_mv |
AT huiqiuzhang clinicaltrialprogressandapplicationofimmunecheckpointinhibitorsinthetreatmentofsmallcelllungcancer AT xiyangli clinicaltrialprogressandapplicationofimmunecheckpointinhibitorsinthetreatmentofsmallcelllungcancer AT xichuanli clinicaltrialprogressandapplicationofimmunecheckpointinhibitorsinthetreatmentofsmallcelllungcancer AT yanjunsu clinicaltrialprogressandapplicationofimmunecheckpointinhibitorsinthetreatmentofsmallcelllungcancer |
| _version_ |
1718420344444813312 |